SCOTT ELIASOF, Ph.D.
Senior Vice President, Research
Scott is the Senior Vice President of Research of Frequency Therapeutics. Previously, Scott was Chief Scientific Officer of Cerulean Pharma, a clinical stage oncology-focused nanomedicine company, where he led all stages of research from discovery through clinical development for the Company’s NDC innovations. The NDC platform created the Company’s proprietary pipeline, including CRLX101 and CRLX301, and was a driving factor behind their collaboration with Novartis. Before that, he was the director of the Chemical Biology Platform at the Broad Institute, directing a multi-disciplinary team of professional scientists and technicians in the fields of synthetic chemistry, analytical chemistry, high-throughput screening, computational science and software engineering. Prior to joining the Broad Institute, Scott worked at Millennium Pharmaceuticals, where he managed scientific teams in cell biology, molecular biology, neuroscience, and bioinformatics for a large-scale genomics-based drug discovery program. Earlier in his career, Scott was at Neurocrine Biosciences, where he played a key role in the exploration of glutamate transporters in the field of stroke and neurological disorders. Scott received his Ph.D. in Neuroscience at University of California, Berkeley, and his B.S in Electrical Engineering at MIT.